Understanding the determinants of myopic choroidal neovascularization and response to treatment.

Related Articles

Understanding the determinants of myopic choroidal neovascularization and response to treatment.

Eur J Ophthalmol. 2016 Nov 04;26(6):511-516

Authors: Leveziel N, Gaucher D, Baillif S, Benouaich X, Chartier C, Grenet T, Gualino V, Krivosic V, Delyfer MN

Abstract
PURPOSE: The pathophysiologic pathways that govern the development of choroidal neovascularization (CNV) are complex. Patchy atrophy and lacquer cracks are known to be major anatomic risk factors for the development of myopic CNV, but they are not alone and much remains to be understood about other factors that influence development. In addition, a greater understanding of the modifiable and nonmodifiable factors that influence outcome, resolution, and recurrence after intravitreal injection of anti-vascular endothelial growth factor (VEGF) could lead to more personalized treatment algorithms that integrate parameters other than the presence of CNV itself and could help improve clinical outcomes and reduce recurrence.
METHODS: We reviewed recently published data on risk factors for CNV and predictors of response to anti-VEGF treatments. In particular, data pertaining to age, sex, genetic predisposition, baseline visual acuity, axial length, staphyloma, lacquer cracks, atrophic lesions, choroidal thickness or choroidal thinning, characteristics of CNV such as duration, localization, and size of CNV, and treatment considerations such as choice of treatment, loading doses, and combination treatments were reviewed.
RESULTS: Our analysis showed that the body of evidence is incomplete.
CONCLUSIONS: Additional studies are required to identify high-risk patients and to develop personalized therapeutic approaches.

PMID: 27515571 [PubMed - indexed for MEDLINE]

http://ift.tt/2mcHVBQ